

BACIL PHARMA LIMITED

CIN: L24200MH1987PLC043427

Registered Office: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099;
Tel: 22618452/22661541; Tel/Fax: 22618327; Email Id: bacilpha@yahoo.com / bacilpharma07@gmail.com; Website: www.bacilpharma.com

Date: 03/07/2026

To,
The General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400001

Scrip Code: 524516

Subject: Intimation of Board Meeting pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 29(1)(d) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 9th July 2026, inter alia, to consider and approve the following:

1. The proposal for raising funds by way of a Rights Issue of equity shares to the eligible equity shareholders of the Company for an aggregate amount of up to ₹50,00,00,000 (Rupees Fifty Crores Only), in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, subject to such statutory and regulatory approvals as may be required.
2. The proposal for increase in the Authorised Share Capital of the Company, if required, to facilitate the proposed Rights Issue and to ensure adequate headroom for issuance of equity shares pursuant thereto.
3. Consequent alteration of the Capital Clause of the Memorandum of Association of the Company and other related documents, if required, subject to the approval of the Board and the shareholders of the Company, as applicable.
4. To determine and approve the detailed terms and conditions of the Rights Issue, including but not limited to the issue size, rights entitlement ratio, issue price, record date, rights issue schedule, appointment of intermediaries, draft Letter of Offer and such other matters incidental or connected therewith.
5. Discussion on Appointment and Resignation of Directors.
6. Any other matter incidental or connected with the proposed Rights Issue and increase in the Authorised Share Capital.

Further, in continuation of our earlier intimation regarding closure of the Trading Window pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company shall remain closed for all designated persons and their immediate relatives until 48 hours after the declaration of the outcome of the aforesaid Board Meeting.

Kindly take the above information on record.

Thanking You,

Yours faithfully,

For Bacil Pharma Limited

Mrs. Chaitali Kalpataru Shah
Director & CFO
DIN: 11167778